We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA ADVISORY COMMITTEE CALLS FOR UPDATE TO SSRI/SNRI LABELING
FDA ADVISORY COMMITTEE CALLS FOR UPDATE TO SSRI/SNRI LABELING
June 10, 2004
Risks from exposure to antidepressants during pregnancy should be communicated in patient labeling, an FDA subcommittee said this week.